ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,257Medicare Part D Prescriptions Filled, Including Refills

Rank: 221 out of 2035

$375K Total Retail Price of All Prescriptions

Rank: 533 out of 2035

303 Patients Receiving at Least One Drug in Part D
68%Patients 65 Years and Older
88% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Michigan
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

22% of this provider’s 303 patients filled at least one prescription for a schedule three drug, compared to an average of 17%.

Risky Drugs to Seniors

2% of this provider’s 8,116 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$41 was the average price of a prescription from this provider, compared to $63 among peers.

Prescriptions per Patient

31 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Michigan
SIMVASTATIN 710 617 1 1
FUROSEMIDE 573 555 2 7
AMLODIPINE BESYLATE 432 372 3 6
LISINOPRIL 415 377 4 3
METOPROLOL TARTRATE 269 260 5 8
LEVOTHYROXINE SODIUM 247 240 6 4
METFORMIN HCL 243 166 7 9
HYDROCHLOROTHIAZIDE 230 190 8 12
HYDROCODONE-ACETAMINOPHEN 194 164 S3 9 2
POTASSIUM CHLORIDE 170 170 10 18
WARFARIN SODIUM 165 156 11 11
OMEPRAZOLE 160 129 12 5
LISINOPRIL-HYDROCHLOROTHIAZIDE 145 95 13 26
ISOSORBIDE MONONITRATE ER 137 126 14 32
ATENOLOL 133 91 15 10
DONEPEZIL HCL 130 130 16 24
NAMENDA 113 113 17 37
LOSARTAN POTASSIUM 107 96 18 15
NOVOLOG MIX 70-30 103 94 19 254
CARVEDILOL 100 96 20 22
RANITIDINE HCL 91 84 21 28
GLIPIZIDE 91 69 21 54
ALBUTEROL SULFATE 87 87 23 90
OLANZAPINE 87 86 23 121
LOSARTAN-HYDROCHLOROTHIAZIDE 81 73 25 47
CRESTOR 77 77 26 41
CLOPIDOGREL 77 62 26 30
ACETAMINOPHEN-CODEINE 72 60 S3 28 52
NOVOLIN R 69 69 29 210
PHENYTOIN SODIUM EXTENDED 63 60 30 132
LIDODERM 63 63 30 72
PENTOXIFYLLINE 62 62 32 285
METOPROLOL SUCCINATE 61 43 33 16
LEVETIRACETAM 59 54 34 87
ALENDRONATE SODIUM 59 51 34 27
HYDRALAZINE HCL 57 57 36 45
ZOLPIDEM TARTRATE 57 55 36 21
SERTRALINE HCL 57 57 36 23
GABAPENTIN 56 32 39 14
PLAVIX 56 55 39 49
ESCITALOPRAM OXALATE 56 56 39 77
CITALOPRAM HBR 55 55 42 20
PRAVASTATIN SODIUM 55 35 42 17
TRIAMTERENE-HCTZ 52 32 44 35
ANASTROZOLE 51 36 45 274
MIRTAZAPINE 50 50 46 46
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.